Who is CYDY_ invest??? I looked back at this post and

New Post Public Reply Private Reply Replies (0) Message Board
Goosebumps CYDY_Invest #92051
635

Who is CYDY_ invest??? I looked back at this post and found that there is much history but only one post ever before. Makes you wonder who didn’t want to be recognized and already uses this board.

Either way... it is good advice and should be read occasionally. It will inform you into what the history has been and help understand that the old management wasn’t what all that great and now they want back in... just give it another read with an OPEN MIND...so you know who we are dealing with.


Hi,

I’ve been an investor for many years and have heard every conf call. Regarding this 5% group, I don’t trust them, and I don’t think anyone should. So it really doesn’t matter what they say, if they’re not credible. As mentioned, former employees Caracciolo and Pestell are part of this group.
Thank you Ohm, for reminding the message board that it was Caracciolo who brought the worthless Prostate test, which has been shelved, and gave Pestell 8 million shares. Pestell was appointed as the CMO (I don’t think he actually has his Board license in the USA, which made no sense to be the CMO.)

“We are very pleased to expand and strengthen our relationship with Dr. Pestell...,” said Anthony Caracciolo, CytoDyn’s Chairman. “As we separately announced today, we have signed a non-binding letter of intent for the proposed acquisition of ProstaGene.” (7/12/18)

This was an absurd decision from Caracciolo to acquire the Prostate test. In addition, I remember during the couple conference calls Caracciolo actually was a part of, I was totally unimpressed by Caraccoilo’s speaking ability and grasp of situations investors brought up. He kept us in the dark for way over a year, and essentially no progress happened with the company. Furthermore, Pestell was terminated by the Board.

So why should we believe this group?

Besides these two individuals, this 5% group includes 2 pizza shop owners, a realtor, a bunch of “consultants.” What possible earth-shattering wisdom will they offer that could make any difference to the value of the company? There is nothing to gain and everything to lose. Regardless of what they advise, they’re not trustworthy. Their true motives cannot be trusted.

I’m very concerned they will take over and put their people in place to sell out cheap to Big Pharma, or some other horrible situation will occur.

At this point, the only thing that really counts are well designed trials and positive data. There’s been tremendous progress this year. There are multiple Covid trials, NASH trial, Cancer basket, BLA submission. There’s more money in the bank than ever in Cytodyn’s history. Let’s be stay the course! We will have data readouts in the very near future and that will mean everything!

Certainly, I’ve been frustrated by Nader’s communication, however he has improved. Also, Dr. Jay vouches for his trustworthiness (on his recent podcast) which is important.

I am very impressed and encouraged by Dr. Scott Kelly. I believe he is a good man, a patient advocate, and he goes the extra mile for Covid patients trying to get Lernonlimab. He’s smart, articulate, knows the science. Listen to the TNBC cancer presentation. He formed the scientific advisory board with top notch physician scientists and leaders in medicine.

As a shareholder, I want minimum dilution, to explore and ultimately get approval for a wide variety of indications, grow the company organically and not selling out cheap to Big Pharma! These align with the goals of Nader, Kelly, and the Board. There’s been tremendous progress this last year and I want to keep the momentum. The FDA letter and this 5% group are bumps in the road, but just gotta keep moving forward, and fully reject this 5% group

Read More: https://investorshangout.com/post/view?id=614...z6wg8H3Chz

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

7-Eleven Rolls Out Korean Flavors in Bold Menu Shift

Updated Category News Views 145

7-Eleven's New Global Menu Twist October 2026 sees 7-Eleven, Inc. whip out an intriguing move, venturing east with its new Flavors of Korea menu. They're not just changing the game in convenience store aisles; they're dancing to the beat of global flavors—a shake-up fit for the world's largest convenience retailer. Think about bodega basics getting a spicy Korean...

Continue Reading
United Imaging Surges with 19.43% Revenue Growth in 2026

Updated Category News Views 18

United Imaging's Remarkable Revenue Surge Coming out of Shanghai, we've got some major numbers to chew on. United Imaging Healthcare (688271.SH)—this isn't your run-of-the-mill medical tech firm—is bringing some serious heat to the market with a 19.43% bump in revenue. We're talking RMB 10.58 billion raked in over just the first nine months of 2026. Those are hefty...

Continue Reading
Bugsy Siegel's Cold Case: Museum Exhibit Revisits Unsolved Murder

Updated Category News Views 72

Whoever thought sleuthing around organized crime’s dark corridors would land you inside Las Vegas' Mob Museum, tracing the cold case trail of none other than Bugsy Siegel? Yeah, the notorious mobster whose murder on June 20, 1947, has remained frozen in mystery like a stiff in cement shoes. Now, as we inch closer to the 80-year mark since Siegel was shot dead in Beverly...

Continue Reading
Abbe Lane's Estate Auction: Glamour Up for Grabs

Updated Category News Views 72

Glamour from the Mid-Century Comes to the Auction Block In a world obsessed with the flavor of the month, a collection that truly turns heads by sailing in on a wave of genuine mid-century splendor isn't something you stumble upon every day. John Moran Auctioneers has the privilege to crack open the vault on the Estate of Abbe Lane, a name that once rolled off tongues...

Continue Reading
West Fraser Tackles Grim Quarter: Indefinite Mill Closures

Updated Category News Views 103

Bracing For Impact: The Tough Truth About West Fraser's Recent Moves Things are looking a bit bleak over at West Fraser Timber Co. They've just dropped their Q3 2026 results, ringing the bell with a hefty $80 million loss. As if that wasn't enough, the company's decided to indefinitely curtail a couple of mills—one in Lanett, Alabama and the other in Leola, Arkansas....

Continue Reading
DODGEN's Tech Advances Chinese POE Projects with Key Wins

Updated Category News Views 85

Milestones Mark a New Era for POE Projects in China Sipping my black coffee, I can’t help but marvel at DODGEN’s recent industrial feats in China's polyolefin elastomer (POE) sector. This year, they’ve notched three critical milestones across some major projects, and it’s worth every grain of your attention if you’re following where the chemical industry’s...

Continue Reading
ASTS Faces Class Action: Investor Warning Ahead

Updated Category News Views 22

AST SpaceMobile: Turbulence Ahead? The latest buzz isn't coming from AST SpaceMobile's satellites but from courtrooms, with a class action lawsuit raising eyebrows among NASDAQ:ASTS investors. It's like watching a high-stakes poker game where cards have hidden costs, and the patience of those holding them is wearing thin. Here's what's truly ruffling feathers. What...

Continue Reading
ODNB and NACB Merge: A Big Leap in Community Banking

Updated Category News Views 0

Merging Titans in Community Banking Folks, we've got a colossal merger happening in the cozy yet combative world of community banking—ODNB Financial Corporation is hitching wagons with National Capital Bancorp, Inc. Now, you'd be forgiven for not popping champagne over this unless your bread is buttered by $2.4 billion in assets and the shiny allure of becoming a big...

Continue Reading
TransCode Pursues Strategic Moves for TTX-MC138 Value

Updated Category News Views 56

A New Chapter for TransCode? Every once in a while, you find companies taking bold steps that make the market look twice. Today, that’s TransCode Therapeutics (NASDAQ: RNAZ) putting their chips on the table, determined to find the best route forward for their oncology efforts. Now, I’ve seen outfits talk plans without substance, but getting Tungsten Advisors on board...

Continue Reading
Navigating Homeowner Deductibles: Balancing Costs

Updated Category News Views 0

Understanding the Basics: Premiums and Deductibles Picture sorting through bills with a cup of lukewarm coffee, wondering if there’s a smarter way to handle homeowner insurance. Chuck Montgomery cuts through the fluff, talking turkey about balancing insurance dollars. One part of the game is deciding your deductible, the sum you fork over before insurance steps in...

Continue Reading